8-K: Ligand Pharmaceuticals to Acquire XOMA Royalty Corp.

Ligand Pharmaceuticals announced its definitive agreement to acquire XOMA Royalty Corporation for approximately $739 million in cash, aiming to expand its royalty portfolio and accelerate profit growth.

Summary

• Ligand Pharmaceuticals is acquiring XOMA Royalty Corporation for $39.00 per share in cash, totaling approximately $739 million.
• The acquisition is expected to significantly expand Ligand's royalty portfolio to over 200 assets, adding seven new commercial products.
• XOMA Royalty stockholders will also receive a non-transferable Contingent Value Right (CVR) per share, entitling them to a portion of net proceeds from certain pending litigation.
• The transaction is anticipated to be immediately accretive to Ligand's adjusted EPS, with an expected $1.50 per share accretion in 2027.
• Ligand has increased its 2026 adjusted EPS guidance to $8.50-$9.50 and its 2026 revenue guidance to $270 million-$310 million.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strongly positive development, with Ligand making a strategic acquisition that is expected to be immediately accretive and significantly enhance its royalty portfolio and long-term growth prospects.

Positives

• Acquisition is expected to be immediately accretive to Ligand's adjusted EPS.
• Ligand increases 2026 adjusted EPS guidance to $8.50-$9.50.
• Ligand increases 2026 revenue guidance to $270 million-$310 million.
• The deal adds seven marketed products and nearly doubles Ligand's portfolio of Phase 2 and 3 assets.
• The combined company will have over 200 royalty assets, diversifying Ligand's portfolio across development stages and therapeutic areas.
• XOMA Royalty stockholders will receive a CVR providing potential upside from ongoing litigation.

Negatives

• The acquisition is subject to customary closing conditions, including XOMA Royalty stockholder approval and regulatory approvals.
• There is a risk that the proposed acquisition may not close.
• The transaction involves significant transaction costs and potential unknown liabilities.
• The integration of the two companies may disrupt business and operational relationships.

Risks

• Risks related to the satisfaction or waiver of closing conditions, including failure to obtain necessary regulatory approvals and XOMA Royalty stockholder approval.
• Possibility of competing offers emerging.
• Risks associated with realizing the anticipated benefits of the acquisition, including potential integration challenges.
• Disruption from the transaction impacting business and operational relationships.
• Potential for litigation and/or regulatory actions related to the acquisition or XOMA Royalty's business.
• Uncertainties regarding the commercial success of existing and pipeline products for both companies.
• Reliance on collaborative partners for milestone payments, royalties, and other revenue projections.
• Risks associated with drug development, clinical trial data interpretation, and regulatory approvals.

Future Outlook

Ligand Pharmaceuticals expects the acquisition of XOMA Royalty to be immediately accretive to its adjusted EPS and has raised its 2026 adjusted EPS guidance to $8.50-$9.50 and revenue guidance to $270 million-$310 million. The company anticipates the transaction will add $1.50 per share to its adjusted EPS in 2027.

Management Comments

• "This acquisition presents a compelling opportunity for us to strengthen and diversify our portfolio across all stages of clinical development and accelerate our long-term profitable growth."
• "This acquisition will add seven marketed products and nearly double our portfolio of Phase 2 and 3 assets, which we believe will create significant value for our stockholders, all through a single transaction."
• "The XOMA Royalty team has built a robust portfolio of complementary biopharmaceutical assets, and this acquisition will enable us to further grow and diversify in areas such as ophthalmology, oncology, CNS and rare diseases."
• "With this agreement, Ligand adds over 120 commercial, clinical, and preclinical stage assets to its broad and growing royalty portfolio highlighted by Roches VABYSMO (faricimab-svoa), Day One Pharmaceuticals OJEMDA (tovorafenib), Zevra Therapeutics MIPLYFFA (arimoclomol), and 14 programs in late-stage development, highlighted by Takedas mezagitamab and certain assets from Takedas externalized asset portfolio, including osavampator, volixibat and OHB-607."
• "After evaluating a broad range of strategic and financing alternatives, we believe combining our diverse portfolio with a company that shares our commitment to helping the biopharmaceutical industry thrive represents the most compelling outcome for XOMA Royalty's stockholders."
• "The structure delivers to our stockholders both the intrinsic value of XOMA's portfolio today and the optionality associated with our ongoing litigation with Janssen Biotech (now Johnson & Johnson Innovative Medicine) via the CVR."

Industry Context

StockSavvy.ai notes that this acquisition aligns with the trend of larger biopharmaceutical companies consolidating royalty portfolios to enhance diversification, accelerate growth, and gain access to a broader range of assets across different development stages and therapeutic areas. Ligand's move to acquire XOMA Royalty strengthens its position as a leading royalty aggregator.

Comparison to Industry Standards

• Ligand's acquisition of XOMA Royalty for $739 million is a significant transaction in the royalty aggregation space, comparable to other large-scale portfolio acquisitions seen in the industry.
• The addition of over 120 commercial, clinical, and preclinical assets, including marketed products like Roche's VABYSMO and Day One Pharmaceuticals' OJEMDA, positions Ligand's portfolio to be among the most diversified in the industry, rivaling other major royalty aggregators.
• The immediate accretion to Ligand's adjusted EPS and increased guidance are metrics often sought by investors in such strategic transactions, indicating successful integration and value creation potential, a benchmark for successful M&A in the sector.

Legal Proceedings

• XOMA Royalty has an ongoing dispute with Janssen Biotech (now Johnson & Johnson Innovative Medicine) regarding the commercialization of TREMFYA, which is the subject of the CVR.

Stakeholder Impact

• Shareholders of XOMA Royalty will receive $39.00 per share in cash and a CVR, providing immediate value and potential future upside.
• Ligand Pharmaceuticals' shareholders are expected to benefit from increased EPS accretion and a strengthened, diversified royalty portfolio.
• Employees of both companies may face uncertainty regarding integration and potential redundancies, though Ligand aims to attract and retain talent.
• Collaborative partners of both companies may see changes in management and operational relationships post-acquisition.

Next Steps

• Obtain approval from XOMA Royalty stockholders.
• Secure necessary regulatory approvals.
• Complete the Holding Company Reorganization and CVR Spin.
• Close the merger transaction, expected in the third quarter of 2026.

Key Dates

Recommendation

The acquisition of XOMA Royalty by Ligand Pharmaceuticals is a strategically sound move that is expected to be immediately accretive to Ligand's earnings, significantly expand its royalty portfolio with high-quality assets, and enhance its long-term growth trajectory. The premium paid is justified by the strategic benefits and the addition of valuable assets and future potential through the CVR. This transaction positions Ligand for continued success in the royalty aggregation market.

Keywords

Merger, Acquisition, Royalty, Biotechnology, Pharmaceuticals, Ligand Pharmaceuticals, XOMA Royalty, SEC Filing